Copertina

Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, Chiaki Matsumoto, Moe Nomura‐Yogo, Yuki Oda, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Kenshi Suzuki, Osamu Hosoya, Tadao Ishida
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Hematological Oncology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Prognostic value of the second revision of the international staging system (R2‐ISS) in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation
di: Taku Kikuchi, et al.
Pubblicazione: (2024)

Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma
di: Taku Kikuchi, et al.
Pubblicazione: (2025)

Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma
di: Danai Dima, et al.
Pubblicazione: (2024)

The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation
di: Yutaka Shimazu, et al.
Pubblicazione: (2024)

Successful treatment of scleromyxedema with daratumumab, lenalidomide and dexamethasone in a patient with multiple myeloma
di: Luca Bettolini, et al.
Pubblicazione: (2024)

Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta‐analysis
di: Bruno Almeida Costa, et al.
Pubblicazione: (2024)

Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma
di: Samia Shabnaz, et al.
Pubblicazione: (2024)

Mechanisms of resistance to daratumumab in patients with multiple myeloma
di: Katrine Fladeland Iversen
Pubblicazione: (2024)

Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis
di: Jahanzaib Khwaja, et al.
Pubblicazione: (2025)

Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from GRIFFIN
di: Rebecca Silbermann, et al.
Pubblicazione: (2024)

No benefit from daratumumab, bortezomib and dexamethasone (D‐Vd) in real‐world patients with functional high‐risk multiple myeloma: A report from the Myeloma and Related Diseases Registry
di: Sueh‐li Lim, et al.
Pubblicazione: (2025)

Preferred standard‐of‐care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologists
di: Rahul Banerjee, et al.
Pubblicazione: (2026)

Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma
di: Ola Landgren, et al.
Pubblicazione: (2025)

Safety and feasibility analysis of rapid daratumumab infusion in Chinese patients with multiple myeloma
di: Xi‐xi Yin, et al.
Pubblicazione: (2024)

Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens
di: Danilo De Novellis, et al.
Pubblicazione: (2024)

Busulfan, melphalan and carfilzomib high‐dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma
di: Patrick Hagen, et al.
Pubblicazione: (2024)

Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse
di: Cyrille Touzeau, et al.
Pubblicazione: (2025)

Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study
di: Ajay K. Nooka, et al.
Pubblicazione: (2024)

Correction to “A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma ( CARAMEL )”
Pubblicazione: (2024)

Genomic architecture and sex chromosome systems of commercially important fish species in Asia – Current status, knowledge gaps and future prospects
di: Khanam Taslima, et al.
Pubblicazione: (2024)

Superconductivity emerging from the N${é}$el state in ${\it infinite}$-${\it stage}$ single-layer cuprate La$_2$CuO$_{4+δ}$
di: Ihara, Yoshihiko, et al.
Pubblicazione: (2025)

Gut dysbiosis and its treatment in patients with critical illness
di: Kentaro Shimizu, et al.
Pubblicazione: (2025)

Analysis of comprehensive biomolecules in critically ill patients via bioinformatics technologies
di: Hisatake Matsumoto, et al.
Pubblicazione: (2024)

Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA
di: Evangelos Terpos, et al.
Pubblicazione: (2024)

Genetic and developmental bases for mammalian neocortical evolution
di: Tadashi Nomura, et al.
Pubblicazione: (2025)

Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib‐based regime
di: Joshua Bomsztyk, et al.
Pubblicazione: (2024)

Possibility of increasing linear energy transfer in multi‐ion radiotherapy for bone and soft tissue sarcomas
di: Hideyuki Takei, et al.
Pubblicazione: (2025)

Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real‐world: The retrospective IMAGE study
di: Olivier Decaux, et al.
Pubblicazione: (2024)

Anticollagenase Therapy for Canine Corneal Ulcers: A Narrative Review of Mechanisms, Efficacy, and Clinical Implementation
di: Takuya Yogo
Pubblicazione: (2026)

Serum Eye Drops for Canine Corneal Disease: A Systematic Review of Epithelial Repair and Clinical Outcomes
di: Takuya Yogo
Pubblicazione: (2026)

Two‐team laparoscopic extended lateral lymph node dissection with transperineal resection of the distal main trunk of internal iliac vein using a linear stapler—A video vignette
di: Yuki Murata, et al.
Pubblicazione: (2024)

Modeling serum M‐protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone
di: Yuki Otani, et al.
Pubblicazione: (2024)

Thalidomide‒dexamethasone combination therapy for a canine myeloma‐related disorder with paraproteinaemia: A third‐line treatment response
di: Diogo Machado, et al.
Pubblicazione: (2026)

Prehospital Variability of Pediatric Emergency Acuity Assessment Criteria in Japan: A Nationwide Analysis of Fire Department Protocols
di: Sakura Minami, et al.
Pubblicazione: (2026)

The shape‐shifting plasma cell: Multiple myeloma with CKS1B amplification
di: Quentin Amiot, et al.
Pubblicazione: (2026)

Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China
di: Xiaoyan Han, et al.
Pubblicazione: (2024)

Preclinical efficacy of carfilzomib in BRAF ‐mutant colorectal cancer models
di: Federica Maione, et al.
Pubblicazione: (2024)

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial
di: Sosana Delimpasi, et al.
Pubblicazione: (2026)

Impact of tablet‐induced electromagnetic interference on abdominal cardiac devices: A study based on simulated patients
di: Yo Kajiyama, et al.
Pubblicazione: (2025)

Fast Sprite Decomposition from Animated Graphics
di: Suzuki, Tomoyuki, et al.
Pubblicazione: (2024)